In this webinar GMU Director of the Laboratory of Molecular Virology Fatah Kachanshi and ATCC Lead Biologist Heather Branscome will cover these key points:

  • Extracellular vesicles (EVs) such as exosomes are critical mediators of intercellular communication. The diverse biological cargo that is associated with these vesicles is believed to mediate the pleiotropic effects of EVs.
  • Damaging EVs contain viral non-coding RNAs and other viral proteins. These EVs can exert deleterious effects on recipient cells; further characterization of damaging EVs may serve for diagnostic purposes.
  • Reparative EVs can contribute to various biological processes ranging from normal cellular development to the repair of damaged and/or diseased tissue. Because of their broad regenerative properties, stem cell EVs are being evaluated as potential replacements for stem cell therapy.

Antimicrobial Resistance II

Arm Your Lab in the Fight Against Superbugs


This second part of a two-part webinar series on antimicrobial resistance, presented by ATCC Scientist Christine Fedorchuk, will provide these key takeaways:

  • Understanding the nature of the problem: explaining the biggest challenges hindering advancement such as financial deficits, implementation of surveillance or new therapies, and the speed of resistance outpacing the speed of scientific research.
  • Explaining progress: scientific and clinical advances, how organizations are contributing to the fight against AMR, and how ATCC is contributing to the fight against AMR.

Dr. Elizabeth Gillies is well-versed in using CRISPR/Cas9 genome-editing technology for creating advanced cell-based models. Watch the presentation to learn how this cutting edge technology was used to enhance virus production in ATCC cell lines

  • Most viral vaccines are manufactured in large-scale tissue culture systems using historical cell lines that are approved for vaccine manufacturing.
  • ATCC used CRISPR/Cas9 gene-editing techniques to increase the viral production efficiency of some of these historical cell lines.
  • These enhanced virus-producing cell lines have the potential to significantly reduce the costs associated with generating viral vaccines and high-titer viral stocks.